valacyclovir

Phase 1/2Completed

0 views this week 0 watching💤 Quiet

Interest: 32/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Infectious Mononucleosis

Conditions

Infectious Mononucleosis

Trial Timeline

Feb 1, 2004 → Sep 1, 2005

NCT ID

NCT00274404

About valacyclovir

valacyclovir is a phase 1/2 stage product being developed by Roche for Infectious Mononucleosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00274404. Target conditions include Infectious Mononucleosis.

What happened to similar drugs?

4 of 19 similar drugs in Infectious Mononucleosis were approved

Approved (4) Terminated (4) Active (11)

🔄LevofloxacinJohnson & JohnsonPhase 3

✅AdalimumabAbbVieApproved

✅Daptomycin + Standard of Care (SOC)MerckApproved

🔄Tedizolid Phophate + Antibiotic comparator + Aztreonam + MetronidazoleMerckPhase 3

❌Daptomycin + Vancomycin + TeicoplaninNovartisPhase 3

❌PTK 0796 + linezolid + moxifloxacinNovartisPhase 3

❌AIN457 + PlaceboNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00274404	Phase 1/2	Completed	Feb 1, 2004	Sep 1, 2005	Infectious Mononucleosis

Competing Products

20 competing products in Infectious Mononucleosis

See all competitors

Product	Company	Stage	Hype Score
levofloxacin	Johnson & Johnson	Phase 2/3	38
Levofloxacin	Johnson & Johnson	Phase 3	40
Adalimumab	AbbVie	Approved	43
Acalabrutinib + Rabeprazole	AstraZeneca	Phase 1	29
Cefepime + Ceftolozane + Meropenem + Piperacillin-Tazobactam + Tazobactam	Merck	Phase 2	35
Daptomycin + Standard of Care (SOC)	Merck	Approved	43
MK-7655 + Imipenem + Cilastatin + Caffeine + Midazolam + Omeprazole	Merck	Phase 1	29
TR-701 200 mg + TR-701 300 mg + TR-701 400 mg	Merck	Phase 2	35
Tedizolid Phophate + Antibiotic comparator + Aztreonam + Metronidazole	Merck	Phase 3	40
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
Daptomycin + Vancomycin + Teicoplanin	Novartis	Phase 3	32
PTK 0796 + linezolid + moxifloxacin	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
Filgotinib + Placebo to match filgotinib + Prednisone	Gilead Sciences	Phase 2	27
Tigecycline + vancomycin with aztreonam	Pfizer	Phase 3	40
Tigecycline	Pfizer	Approved	43
Avibactam sodium/Ceftazidime hydrate	Pfizer	Pre-clinical	33